VKTX
Viking Therapeutics, Inc.
$24.40
-5.54%
2026-10-23
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Key Fundamentals
Forward P/E
-8.08
EPS (TTM)
$-4.67
ROE
-88.9%
Profit Margin
0.0%
Debt/Equity
1.00
Price/Book
10.16
Beta
0.68
Market Cap
$4.43B
Avg Volume (10D)
10.5M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$43.10
60D Low
$24.36
Avg Volume
4.8M
Latest Close
$24.40
Get breakout alerts for VKTX
Sign up for Breakout Scanner to receive daily notifications when VKTX triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Viking Therapeutics, Inc. (VKTX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors VKTX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. VKTX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.